Recently, the Clinical Laboratory Center (NCCL) of the National Health Commission released the results report of the "2023 National Solid Tumor Somatic Mutation High Throughput Sequencing Laboratory Quality Assessment (NCCL-I-28-2023)". Shanghai Epione Medlab a subsidiary of Dunwill Medical, passed the assessment with full marks once again! This fully proves that the testing ability and quality management level of Epione Medlab have been recognized by national authoritative institutions.

This evaluation used the "Tumor Precision Medicine 70 Genes and MSI Joint Testing" independently developed by the parent company Dunwill Medical. This panel contains 70 targeted therapy related genes and chemotherapy drug metabolism related genes recommended by the NCCN and CSCO guidelines for major cancers such as lung cancer, colorectal cancer, gastrointestinal stromal tumors, and cholangiocarcinoma. The detection range covers all exon regions of the genes, and over 200 microsatellite instability sites are selected. DNA and RNA mutations and microsatellite instability are synchronously detected, providing patients with more treatment options such as targeted drugs, chemotherapy drugs, and immune drugs.

Epione Medlab’s passing with a full score, once again proves that its high throughput sequencing technology's professionalism and data analysis ability are recognized by authoritative institutions, and it has a leading position in the domestic testing industry. In the future, Epione Medlab will continue to uphold the service concept of striving for excellence, continuously improve the level of laboratory technical services, and continue to provide customers with higher quality products and services!